Milenic DE - Search Results

1

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH. Kashmiri SV, et al. Among authors: milenic de. Hybridoma. 1995 Oct;14(5):461-73. doi: 10.1089/hyb.1995.14.461. Hybridoma. 1995. PMID: 8575795

2

Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.

Hand PH, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, Garmestani K, Gansow O, Schlom J, Kashmiri SV. Hand PH, et al. Cancer Immunol Immunother. 1992;35(3):165-74. doi: 10.1007/BF01756183. Cancer Immunol Immunother. 1992. PMID: 1638552 Free PMC article.

3

Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.

Abergel C, Padlan EA, Kashmiri SV, Milenic D, Calvo B, Schlom J. Abergel C, et al. Proteins. 1993 Dec;17(4):438-43. doi: 10.1002/prot.340170411. Proteins. 1993. PMID: 8108385

4

Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.

Colcher DM, Milenic DE, Schlom J. Colcher DM, et al. Among authors: milenic de. Targeted Diagn Ther. 1992;6:23-44. Targeted Diagn Ther. 1992. PMID: 1576348 Review. No abstract available.

5

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, et al. Slavin-Chiorini DC, et al. Among authors: milenic de. Cancer Res. 1995 Dec 1;55(23 Suppl):5957s-5967s. Cancer Res. 1995. PMID: 7493377

6

In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response.

Prasad GL, Lee HS, Iwahashi M, Milenic DE, Abrams S, Schlom J, Kashmiri SV. Prasad GL, et al. Among authors: milenic de. Cancer Gene Ther. 1997 Jul-Aug;4(4):253-9. Cancer Gene Ther. 1997. PMID: 9253511

7

Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.

Tamura M, Milenic DE, Iwahashi M, Padlan E, Schlom J, Kashmiri SV. Tamura M, et al. Among authors: milenic de. J Immunol. 2000 Feb 1;164(3):1432-41. doi: 10.4049/jimmunol.164.3.1432. J Immunol. 2000. PMID: 10640759

8

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.

Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV. Iwahashi M, et al. Among authors: milenic de. Mol Immunol. 1999 Oct-Nov;36(15-16):1079-91. doi: 10.1016/s0161-5890(99)00094-2. Mol Immunol. 1999. PMID: 10698310

9

A CDR-grafted (humanized) domain-deleted antitumor antibody.

Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH. Slavin-Chiorini DC, et al. Among authors: milenic de. Cancer Biother Radiopharm. 1997 Oct;12(5):305-16. doi: 10.1089/cbr.1997.12.305. Cancer Biother Radiopharm. 1997. PMID: 10851481

10

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J. Kashmiri SV, et al. Among authors: milenic de. Crit Rev Oncol Hematol. 2001 Apr;38(1):3-16. doi: 10.1016/s1040-8428(00)00133-5. Crit Rev Oncol Hematol. 2001. PMID: 11255077 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters